In recent clinical trials small molecule drugs that target the CFTR protein and rectify either processing (‘correctors’) or gating defects (‘potentiators’) have proven beneficial for some CF patients carrying specific mutations (Ramsey et al., 2011), underscoring the importance of understanding the structure and mechanism of this disease-associated protein at a molecular level. Here, CFTR is linked to cystic fibrosis.